STS & Cancer: New 9-Gene Test Predicts Metastasis

The persistent challenge of predicting which cancer patients will develop distant metastases – the deadliest aspect of the disease – just took a significant leap forward. Researchers have developed a 9-gene classifier demonstrating remarkable accuracy in forecasting metastatic risk not only in soft-tissue sarcoma (STS), but also across several other major cancer types. This isn’t simply incremental progress; it suggests a fundamental biological signature governing metastasis may have been identified, offering a potential paradigm shift in personalized cancer treatment and risk stratification.

For years, oncologists have struggled with the heterogeneity of cancer – the fact that even within the same cancer type, tumors behave differently. Existing prognostic tools, like CINSARC, while valuable, often fall short in accurately predicting which patients will experience distant spread. This new 9-gene classifier, developed through rigorous machine learning analysis of thousands of tumor samples, appears to address this gap. The genes identified – TNXB, ABCA8, ACTN1, EIF4EBP1, PVR, CLIC4, STAU2, ATAD2, and TBC1D31 – consistently correlated with metastasis-free survival across multiple datasets. The fact that this signature transcends cancer type is particularly compelling, hinting at conserved mechanisms driving metastatic progression.

The implications extend beyond STS, a relatively rare cancer. The classifier’s ability to identify breast cancer subgroups likely to benefit from adjuvant chemotherapy is a particularly exciting finding. Currently, chemotherapy decisions are often based on broad clinical characteristics. This tool could enable a more precise approach, minimizing toxicity for patients who wouldn’t benefit and maximizing effectiveness for those who would. The success in kidney clear cell carcinoma and uveal melanoma further solidifies the potential for broad applicability.

The Forward Look

While the research is promising, several key steps remain before this classifier becomes a standard part of clinical practice. The researchers themselves acknowledge the need for validation using formalin-fixed, paraffin-embedded tissue – the standard sample type in diagnostic pathology. This is a critical hurdle, as gene expression profiles can differ between fresh-frozen and preserved tissues. Furthermore, the model’s limited performance in pediatric rhabdomyosarcoma highlights the need for subtype-specific or age-related refinements.

However, the most significant next step will be prospective clinical trials. These trials will need to demonstrate that incorporating this 9-gene classifier into treatment algorithms actually improves patient outcomes. Expect to see collaborations between research institutions and pharmaceutical companies to fund and execute these trials within the next 18-24 months. Beyond validation, the research opens the door to exploring these 9 genes as potential therapeutic targets. If these genes are indeed central to the metastatic process, disrupting their function could offer a novel approach to preventing cancer spread. The field is poised for a wave of follow-up studies aimed at unraveling the precise mechanisms by which these genes influence metastasis, and translating this knowledge into tangible benefits for patients.

References

1. Tanabe A, Ndzinu J, Sahara H. A novel 9-gene classifier for predicting distant metastasis of soft-tissue sarcoma and multiple malignancies. Clin Treat Res Commun. Published online November 28, 2025. doi:10.1016/j.ctarc.2025.101046

2. Callegaro D, Tinè G, Oppong FB, et al. CINSARRC and sarculator in patients with primary retroperitoneal sarcoma: a combined analysis of single-institution data and the EORTC-STBSG-62092 trial (STRASS). Clin Cancer Res. 2025;31(15):3239-3249 doi:10.1158/1078-0432.CCR-25-0099